The French drugmaker is nearing a decision to invest between 1.3 billion euros and 1.5 billion euros ($1.4-$1.6 billion) at a major production site in Frankfurt, Germany, where it makes insulin brand Lantus, newspaper Handelsblatt reported.
Tag Archive for: Investment
The new investment will create more than 500 jobs and significantly strengthen France’s ability to control the production of essential medicines from start to finish, the company states.
Their investment pledges came as President Emmanuel Macron prepared to kick off today’s annual ‘Choose France’ event aimed at wooing big overseas businesses and investors.
Hedge fund Shah Capital on Monday urged Novavax shareholders to vote against the re-election of three directors and opposed proposals related to executive compensation, weeks after pushing for a board shakeup at the COVID-19 vaccine maker.
Three core trends emerge as pivotal forces driving the healthcare sector forward: strategic responses to economic uncertainty, the accelerated growth in AI investments, and the groundbreaking advancements in next-generation medications. Together, these trends do not merely represent shifts within the health sector; they signal a critical tipping point, one that demands adaptability, foresight, and an unwavering focus on innovation to navigate the future of health care.
The company’s planned investment includes 450 million pounds to research, develop and manufacture vaccines at its manufacturing site in Speke, Liverpool, and another 200 million pounds to expand its existing presence in Cambridge, where its global headquarters are located.
The financing was secured from life sciences investment company Abingworth and will help Gilead run “select clinical studies” of Trodelvy.
At yesterday’s Oncology Innovation Day, Pfizer laid out its business strategy which includes building up its biologics business, specifically antibody-drug conjugates and bispecific antibodies.
Rare diseases currently afflict 300 million people worldwide and 30 million people in the U.S. alone. However, 95% of these diseases lacked an FDA-approved treatment as of January 2023. One reason, industry leaders say, is cost.
In an interview with Med Ad News, Leo Tarkovsky, chief commercial officer at Fingerpaint Group discusses the transformation in what clients want and need with respect to their partners, along with the evolving expectations of healthcare companies.